[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605926":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":11,"centralContacts":16,"locations":26,"responsibleParty":46,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Epiliquid Holding, Inc","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Cases: Average-risk population undergoing colorectal cancer screening colonoscopy",null,[12],{"name":13,"affiliation":14,"role":15},"Emanuel Campoy, PhD","CONICET-National Scientific and Technical Research Council","STUDY_DIRECTOR",[17,22],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Dr. Victoria Bocanegra, MD, PhD.","CONTACT","+5492616603254","victoria.bocanegra@epiliquid.com",{"name":23,"role":19,"phone":24,"phoneExt":10,"email":25},"Dr. Emanuel Campoy, PhD.","+5492615997899","emanuel.campoy@epiliquid.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Epiliquid","RECRUITING","Mendoza","Mendoza Province","5500","Argentina","AR",{"type":36,"coordinates":37},"Point",[38,39],-68.84582,-32.88946,{"lat":39,"lon":38},[42],{"name":43,"role":19,"phone":44,"phoneExt":10,"email":45},"Alejandro Ledesma, M.Sc","+549 1140681732","alejandro.ledesma@epiliquid.com",{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100605926","colon-cancer-liquid-biopsy-investigation-of-methylation-based-biomarkers-evaluation-using-delta-hld-climbed-100605926",false,"NCT07168876","Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)","Clinical Validation Cross-sectional Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CLIMBED)","CLIMBED","Inclusion Criteria:\n\n* Men and women aged 45-75 years\n* Indication of colorectal cancer screening colonoscopy by treating physician\n\nExclusion Criteria:\n\n* First-degree family history of CRC\n* Inflammatory bowel disease (ulcerative colitis, Crohn's disease)\n* Other malignancies within 5 years\n* Known hereditary CRC syndromes (Lynch, FAP)\n* Major trauma, surgery, transfusion in past 30 days\n* Current participation in an interventional clinical trial",true,"ALL","45 Years","75 Years",{"count":61,"type":62},3200,"ESTIMATED","OBSERVATIONAL","CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.",[66],"Colorectal Cancer (CRC)",[68,69,70,71,72,73,74],"Colorectal cancer","Epigenetics","Liquid biopsy","cfDNA","Biomarker","Methylarion","PCR","2025-09-04",{"date":77,"type":78},"2025-09-11","ACTUAL",{"date":80,"type":78},"2024-04-04",{"date":82,"type":62},"2028-12",{"name":5,"class":6},1]